文章名稱引用次數(shù)

• A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors21
• Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee17
• High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)13
• Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B12
• Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)11
• Regional variation and cost implications of prescribed extended half-life factor concentrates among US Haemophilia Treatment Centres for patients with moderate and severe haemophilia11
• Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review10
• Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein9
• Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels8
• First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries8